Adinazolam

Error creating thumbnail:

Adinazolam.svg

Adinazolam is a benzodiazepine derivative with anxiolytic, antidepressant, and sedative properties. It was developed in the 1970s by Dr. Jackson B. Hester at the Upjohn Company. Adinazolam is structurally related to alprazolam and diazepam.

Pharmacology

Adinazolam functions by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, which results in its anxiolytic and sedative effects. It is metabolized in the liver to its active metabolite, N-desmethyladinazolam, which also possesses pharmacological activity.

Medical Uses

Adinazolam has been studied for its potential use in treating anxiety disorders and depression. However, it is not widely used in clinical practice and is not approved by the Food and Drug Administration (FDA) for these indications.

Side Effects

Common side effects of adinazolam include drowsiness, dizziness, and fatigue. As with other benzodiazepines, there is a risk of dependence and withdrawal symptoms with prolonged use.

Legal Status

Adinazolam is classified as a Schedule IV controlled substance under the Controlled Substances Act in the United States, indicating it has a lower potential for abuse relative to substances in Schedule III but can still lead to physical or psychological dependence.

See Also

• Benzodiazepine
• Anxiolytic
• Sedative
• Alprazolam
• Diazepam

External Links

This benzodiazepine-related article is a stub. You can help WikiMD by expanding it.